Drug use further reduces the number of eligible workers

You have a job opening. The position pays $18 to $22 an hour with full benefits and does not require a college degree. By every measure, it should fill quickly.

It does not fill. Applications come in steadily, but a significant portion of candidates fail the pre-employment drug screen before the first day of work. This is not a new problem, but in 2025, drug use among the working-age population has reached levels that are reshaping how employers hire, what they pay for workers’ compensation, and how they manage risk across the board.

This guide explains what the current data shows, which substances are driving the problem, and what you can do right now to protect your workforce and your bottom line.

A manufacturing plant hiring manager reviews drug test results at his desk, illustrating how drug use reduces the pool of eligible workers.

What Does Drug Use Have to Do With Your Hiring Problem?

Drug use among working-age adults is directly reducing the pool of qualified applicants available to employers. Pre-employment drug testing screens out candidates in industries like manufacturing at failure rates reaching 50% in some regions, leaving well-paying jobs unfilled for months while production suffers and competitors pull ahead. The mechanics of how drug use compounds existing hiring pressures are more specific than most employers realize.

The connection between drug use and hiring shortfalls is not theoretical. Annual workforce drug positivity data confirms that failure rates remain meaningfully elevated across all sectors. The problem compounds existing pressures that employers already face:

  • Low unemployment means fewer applicants overall
  • Rising wages create pressure to fill open roles faster
  • Drug use further filters an already shrinking candidate pool
  • Industries with mandatory testing (manufacturing, transportation, construction) feel this most acutely

The manufacturers in Youngstown, Ohio, who first made national headlines for this drug use problem are not outliers. Across the Midwest and Sun Belt, employers in physical trades consistently report that failing a drug test is one of the most common disqualifiers in the screening process, often surpassing skills gaps or background check issues.

The competitor filling the orders these employers cannot? In more than a few cases, it is a German manufacturer operating with a structurally different workforce, not a cheap labor market from Asia. That detail should land.

Is drug use driving up your workers’ comp costs? Contact us to talk through what a properly structured drug-free workplace program means for your premium.

How Many Applicants Are Actually Failing Drug Tests?

Nationwide, the overall workforce positivity rate was 4.4% in 2024, but post-accident drug positivity hit 7.3% and for-cause testing shows a 33.1% positivity rate. These headline numbers understate the real problem. The gap between what pre-employment screens catch and what random and post-accident tests reveal changes the strategic response employers need to consider.

The exact failure rate depends on industry, region, and which substances are included in the testing panel. Nationwide, the overall workforce positivity rate was 4.4% in 2024, but the general workforce rate for non-safety-sensitive roles reached 5.7% in 2023, and post-accident drug positivity hit 7.3% in 2024, just below the all-time record set the prior year. The numbers behind the headlines tell the real story.

Here is what the most recent testing data shows:

Drug Category

General Workforce Positivity

Notable Trend

Marijuana

4.5%

Stable but remains highest

Amphetamines

1.7%

Rising year over year

Fentanyl (random tests)

1.13%

Rising sharply

Fentanyl (pre-employment)

0.14%

Gap reveals post-hire use

Post-accident (all substances)

7.3%

Near record high

For-cause testing (all substances)

33.1%

Confirms ongoing use

A few numbers stand out in particular:

  • For-cause testing shows a 33.1% positivity rate, meaning when employers test on reasonable suspicion, nearly one in three results comes back positive
  • Fentanyl detection in random tests is 8 times higher than in pre-employment screens, which strongly suggests workers are concealing use to pass initial hiring tests
  • Test tampering surged over 600% in 2023, another sign that drug use is not declining but is being hidden more aggressively

The post-employment data tells the most important part of this story. Drug use is not stopping after hire. Workers who pass initial screens are continuing to use, and the accident and claims data reflects that.

The Three Substances Creating the Most Risk in 2025

Marijuana, fentanyl, and amphetamines are the three categories of drug use creating the most hiring and insurance problems for employers in 2025. Each presents a distinct challenge and requires a different response. The substance creating the most hidden ongoing risk in your workforce is likely not the one generating the most paperwork in your HR department.

Marijuana

Despite legalization across more than two dozen states, marijuana remains a Schedule I controlled substance under federal law, as classified by the U.S. Drug Enforcement Administration. Employers in safety-sensitive roles retain the right to require testing and deny employment based on a positive result in virtually every state. The challenge is detection methodology: standard urine tests detect marijuana for up to 30 days from last use, making it impossible to distinguish weekend recreational use from active workplace impairment.

With a 4.5% positivity rate in the general workforce, marijuana remains the leading drug use disqualifier across all industries.

Fentanyl

Fentanyl is approximately 100 times more potent than morphine and 50 times more potent than heroin. The gap between fentanyl’s pre-employment detection rate (0.14%) and its random testing rate (1.13%) is the most alarming signal in current workplace drug data. Workers are passing initial screens and using after hire. In safety-sensitive environments, even a single impaired employee creates multi-million-dollar liability exposure.

Amphetamines

Amphetamine positivity reached 1.7% in 2024 and has trended upward for multiple consecutive years. Prescription stimulants (Adderall, Ritalin) are widely abused, and their detection on standard drug panels creates medical privacy considerations alongside legitimate safety concerns for employers running heavy equipment, vehicles, or industrial machinery.

How Drug Use Drives Up Your Workers’ Compensation Costs

Employees who test positive for substance use file three to five times more workers’ comp claims than those who do not, carry 300% higher medical costs per claim, and account for an estimated 38 to 50% of all WC claims filed. The financial exposure does not stop at the incident itself. It compounds through your experience mod for years after a single claim closes.

Understanding this relationship is critical for any employer managing WC premiums. Your workers’ compensation insurance costs are calculated against your claims history, and drug-related incidents drive that history in three compounding directions:

  • Frequency: Impaired workers have accidents at significantly higher rates
  • Severity: Injuries involving impaired workers tend to be more serious and more costly
  • Duration: Employees with substance use disorders miss more work days during recovery, extending claim timelines

The cost data underscores the stakes:

  • Substance use disorders cost employer health plans $35.3 billion annually
  • WC prescription costs per claim rose 4.3% in 2024, even as general opioid prescribing declined, driven by specialty medications
  • Post-accident drug positivity sits at 7.3%, near the highest rate ever recorded

Your experience modification rate (Xmod) is the multiplier your insurer uses to calculate your WC premium. Every drug-related claim raises your Xmod and compounds your cost exposure for three to five years. Reviewing your workers’ comp class codes and understanding how risk is categorized in your industry is the starting point for taking control of where that premium is headed.

Real-World Example

A mid-sized parts manufacturer running three shifts reported that of 200 job applications received in a single quarter, 94 failed the pre-employment drug screen. An additional 11 current employees tested positive during post-accident or for-cause testing in the same period. Total costs included four WC claims with impairment as a contributing factor, one OSHA recordable incident, and a 0.22-point increase to the company’s Xmod. Annualized premium impact: approximately $34,000 in additional workers’ comp expense. The drug-free workplace program they implemented reduced their positivity rate by 60% over the following 18 months.

The connection between drug use and rising workers’ comp costs shows up directly in claims data. Understanding how to structure a drug-free workplace program that insurers recognize is the first step toward building a premium advantage over competitors who have not made this investment.

How Manufacturers Can Lower Workers’ Comp Costs

Want to understand how drug use is affecting your Xmod right now? Book a call with The Coyle Group and we will walk through your claims history and premium drivers together.

Should You Relax Your Drug Testing Standards?

Employers who soften drug testing standards in response to hiring shortages see measurable increases in workplace injuries, workers’ comp claims, and absenteeism. The short-term hiring gain trades directly for long-term costs that consistently exceed the benefit, often by a wide margin. But maintaining the status quo is not the full answer either. What the data actually supports is a more targeted approach to program design.

When half of applicants are failing screens, it is tempting to ask whether the testing program itself is the obstacle. Here is why it is not the right question to ask:

  • Workers’ comp insurers offer premium credits for documented drug-free workplace programs. Eliminating testing removes those credits immediately.
  • OSHA recordable incident rates correlate directly with substance use in the workforce. More incidents invite more scrutiny and higher insurance costs.
  • A drug-related workplace fatality exposes employers to personal injury litigation that extends well beyond the workers’ comp system.
  • Drug testing costs average $30 to $50 per test. A single serious WC claim averages tens of thousands of dollars. The math is straightforward.

What does make sense is reviewing which substances your panel covers, ensuring your testing methodology is compliant with state law, and building clear return-to-duty protocols for employees who seek treatment. The goal is a defensible, consistently applied program, not a punitive one that ignores legal complexity.

How a Drug-Free Workplace Policy Protects Your Business

A formally documented drug-free workplace policy qualifies your business for workers’ comp premium credits, creates the evidentiary foundation to contest fraudulent claims, and in states that apply causation standards, a positive post-accident test can reduce or eliminate WC benefit liability. Most employers treat this as a compliance checkbox. The ones seeing measurable premium reductions treat it as an operating system for risk reduction.

A formally documented drug-free workplace policy does more than reduce injuries. It qualifies your business for insurance discounts, demonstrates due diligence to regulators and carriers, and creates the evidentiary foundation needed to contest fraudulent or exaggerated workers’ comp claims.

A complete drug-free workplace program includes:

  • Written policy: Clearly defines prohibited substances, testing triggers, consequences, and employee rights
  • Supervisor training: Equips managers to identify behavioral signs of impairment and document observations correctly
  • Pre-employment testing: Covers all new hires, contractors, and temporary workers
  • Random testing: Closes the gap between initial hiring screens and ongoing drug use
  • Post-accident testing: Establishes causation records and protects claim defensibility
  • Return-to-duty protocols: Provides a structured path for employees completing treatment, reducing long-term turnover
Close-up of a drug-free workplace policy binder next to a workers compensation insurance folder, representing how drug use affects business insurance costs.

What 40+ years of working with employers across industries has shown

One area many employers overlook: drug testing compliance is increasingly state-specific. With marijuana legalization expanding and federal reclassification discussions ongoing, a policy written in 2019 may no longer be legally defensible in your state today. An annual review of your drug-free workplace program by a qualified risk advisor is now a standard operating cost, not an optional line item.

Frequently Asked Questions About Drug Use and Workforce Eligibility

Drug use creates a specific and measurable set of hiring and insurance problems for employers, and most questions about testing, compliance, and cost reduction have direct answers that are more actionable than the legal complexity suggests.

In most cases, yes. Employers in safety-sensitive industries retain the right to test for marijuana and deny employment based on a positive result, even where recreational use is permitted. Federal contractors must maintain drug-free workplace programs regardless of state law. The DEA continues to classify marijuana as a Schedule I controlled substance.

Post-accident drug testing data from 2024 shows a 7.3% positivity rate, meaning roughly 1 in 14 workers involved in accidents tests positive. For-cause testing shows a 33.1% positivity rate. The actual contribution of drug use to accident causation is likely higher, as impairment is not always detected immediately.

Yes. Drug-free workplace certifications qualify businesses for workers’ comp premium credits in most states, typically ranging from 5% to 15%. For employers paying $100,000 or more annually in WC premiums, that is a material savings that often exceeds the cost of running the program.

Standard urine tests detect marijuana for up to 30 days from last use. Blood tests detect it for 1 to 4 days. Hair follicle tests detect use for up to 90 days. A positive urine result does not indicate impairment at the time of the test, only that the substance was used within the detection window.

Fentanyl and amphetamines are the fastest-growing concerns based on 2024 testing data. Fentanyl detection in random workplace tests is 8 times higher than in pre-employment screens. Amphetamine positivity reached 1.7% in 2024, continuing a multi-year upward trend. Both represent acute safety risks in physical work environments.

Document the result immediately, notify your insurance carrier, and follow your established return-to-duty policy. A positive post-accident test does not automatically eliminate the employee’s workers’ comp benefits in most states, but it establishes a causation record that is relevant to claim management. Work with your broker to ensure your WC policy and drug-free workplace policy are aligned and current.

About the Author

This article was written by Gordon B. Coyle, CPCU, ARM, AMIM, PWCA, CEO of The Coyle Group, who has over 40 years of experience working with business owners of all sizes and industries across the US, solving their insurance challenges.

Check Out Our Blogs